South Korea Blood Based Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Type (Genetic Biomarkers and Cell-Based Biomarker), By Application (Cancer and Neurological Diseases), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction), and South Korea Blood Based Biomarkers Market Insights, Industry Trend, Forecasts to 2035

  South Korea Blood Based Biomarkers Market Insights Forecasts to 2035

• The South Korea Blood Based Biomarkers Market Size Was Estimated at USD 168.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.11% from 2025 to 2035
• The South Korea Blood Based Biomarkers Market Size is Expected to Reach USD 358.7 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Blood Based Biomarkers Market is anticipated to reach USD 358.7 Million by 2035, growing at a CAGR of 7.11% from 2025 to 2035. The market is expanding as a result of factors including the increased prevalence of ailments like kidney, neurological, diabetic, and cardiovascular conditions.

Market Overview

The study, creation, and marketing of quantifiable markers present in blood samples that can be used to evaluate healthy biological processes, identify illnesses, track the course of diseases, or gauge how well therapies are working are all included in the market for blood-based biomarkers. These biomarkers which may be proteins, nucleic acids, or other molecules are essential for a number of uses, such as clinical research, medication development, customized treatment, and diagnostics. Personalized medicine techniques can be facilitated by the use of biomarkers to assist in stratifying patients into subgroups that are more likely to respond to particular therapies. They are essential in keeping an eye on age-related and chronic illnesses including diabetes and heart disease, which allows for prompt modifications to treatment regimens. The need for early and precise diagnosis utilizing blood-based biomarkers is being driven by an increase in the frequency of neurological conditions including Alzheimer's and cancer. Blood-based biomarkers are essential for customizing treatment plans to each patient's unique profile, which helps to advance precision oncology and personalized medicine. Globally, governments are funding the study and creation of blood-based biomarkers, particularly for neurological and cancer conditions. This grant aids in the development of sophisticated diagnostic instruments as well as the identification and verification of novel biomarkers.

Report Coverage

This research report categorizes the market for South Korea blood based biomarkers market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea blood based biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea blood-based biomarkers market.

Driving Factors

The increasing demand for non-invasive diagnostic tools that enable early disease detection and personalized treatment. The growing prevalence of chronic diseases like cancer and neurological disorders fuels market growth. Technological advancements, such as next-generation sequencing and improved assay sensitivity, enhance biomarker accuracy. Additionally, rising healthcare expenditure and government initiatives promoting precision medicine accelerate adoption.

Restraining Factors

High development and validation costs, including extensive research, clinical trials, and regulatory approvals, can deter small and emerging companies from entering the biomarker space, limiting innovation. Regulatory hurdles present significant barriers, as obtaining approval for new biomarkers can be a lengthy and complicated process.

Market Segmentation

The South Korea blood-based biomarkers market share is classified into type, application, and technology.

• The genetic biomarkers segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea blood-based biomarkers market is segmented by type into genetic biomarkers and cell-based biomarker. Among these, the genetic biomarkers segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. The growing significance of genetic indicators in precision oncology is demonstrated by the pan-cancer approval of companion diagnostics (CDx) for malignancies with RET and NTRK fusion.

• The cancer segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea blood based biomarkers market is segmented by application into cancer and neurological diseases. Among these, the cancer segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The rising cancer prevalence, early diagnosis demand, and advancements in biomarker technology. Blood-based tests offer minimally invasive, accurate cancer detection, driving adoption. Increased government support and awareness further fuel growth.

• The next-generation sequencing segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea blood based biomarkers market is segmented by technology into next-generation sequencing and polymerase chain reaction. Among these, the next-generation sequencing segment dominated share in 2024 and is expected to grow at a significant CAGR during the forecast period. Its high accuracy, ability to analyze multiple genes simultaneously, and suitability for personalized medicine. Technological advancements, decreasing costs, and growing adoption in cancer and genetic disease diagnostics.

 Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea blood based biomarkers market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• GeneMatrix Inc.
• GC Biopharma
• Seegene
• Helixmith
• Macrogen
• ToolGen
• Bioneer
• MEDIcheck
• Genexine
• PharmAbcine
• Samkwang Medical Laboratories
• PhileKorea
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea blood based biomarkers market based on the below-mentioned segments:

 South Korea Blood-Based Biomarkers Market, By Type

• Genetic Biomarkers
• Cell-Based Biomarker

South Korea Blood Based Biomarkers Market, By Application

• Cancer
• Neurological Diseases

South Korea Blood Based Biomarkers Market, By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction